221 related articles for article (PubMed ID: 28249601)
1. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
Stenman A; Murtha T; Korah R; Carling T
Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
4. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
5. SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior.
Brown TC; Murtha TD; Rubinstein JC; Korah R; Carling T
Cell Commun Signal; 2018 Jun; 16(1):27. PubMed ID: 29884238
[TBL] [Abstract][Full Text] [Related]
6. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
7. Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors.
Doghman M; Arhatte M; Thibout H; Rodrigues G; De Moura J; Grosso S; West AN; Laurent M; Mas JC; Bongain A; Zambetti GP; Figueiredo BC; Auberger P; Martinerie C; Lalli E
J Clin Endocrinol Metab; 2007 Aug; 92(8):3253-60. PubMed ID: 17566092
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells.
Xiang T; Li L; Yin X; Zhong L; Peng W; Qiu Z; Ren G; Tao Q
J Cell Mol Med; 2013 Oct; 17(10):1236-46. PubMed ID: 23890219
[TBL] [Abstract][Full Text] [Related]
9. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
10. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
11. Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.
Gu YM; Ma YH; Zhao WG; Chen J
World J Gastroenterol; 2011 Sep; 17(33):3810-7. PubMed ID: 21987623
[TBL] [Abstract][Full Text] [Related]
12. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
13. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
Salomon A; Keramidas M; Maisin C; Thomas M
Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.
Dellinger TH; Planutis K; Jandial DD; Eskander RN; Martinez ME; Zi X; Monk BJ; Holcombe RF
Gynecol Oncol; 2012 Aug; 126(2):259-67. PubMed ID: 22555103
[TBL] [Abstract][Full Text] [Related]
15. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
17. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
18. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
19. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin.
Lee EJ; Jo M; Rho SB; Park K; Yoo YN; Park J; Chae M; Zhang W; Lee JH
Int J Cancer; 2009 Jan; 124(2):287-97. PubMed ID: 19003969
[TBL] [Abstract][Full Text] [Related]
20. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]